Association of CETP Gene Variants With Risk for Vascular and Nonvascular Diseases Among Chinese Adults
Open Access
- 1 January 2018
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA Cardiology
- Vol. 3 (1) , 34-43
Abstract
Observational epidemiologic studies have reported that low plasma concentrations of high-density lipoprotein (HDL) cholesterol are an independent risk factor for occlusive cardiovascular disease (CVD), including coronary heart disease (CHD) and ischemic stroke.1,2 Given these associations, therapeutic strategies to reduce CVD risk by increasing HDL cholesterol concentrations have attracted considerable interest. One such approach is through pharmacologic inhibition of cholesterol ester transfer protein (CETP), which transfers esterified cholesterol from HDL to apolipoprotein B–containing lipoproteins, including very low-density lipoprotein (VLDL), in exchange for triglycerides.3 The first CETP inhibitor assessed in phase 3 trials, torcetrapib, was associated with increased CVD risk, probably owing to off-target effects.4,5 Subsequent trials of dalcetrapib (which had only modest effects on HDL cholesterol) or evacetrapib (which increased HDL cholesterol levels substantially and lowered LDL cholesterol levels) were stopped early for futility after 2 to 3 years of treatment in high-risk individuals.6,7 A trial of the potent CETP inhibitor anacetrapib (which doubled HDL cholesterol levels and lowered non-HDL cholesterol levels by about one-fifth) that involved approximately 30 000 high-risk individuals treated for 4 years recently reported a benefit for risk of major coronary events consistent with the effects of lowering non-HDL cholesterol levels.8Keywords
This publication has 40 references indexed in Scilit:
- Use of allele scores as instrumental variables for Mendelian randomizationInternational Journal of Epidemiology, 2013
- Measurement of LDL-C after treatment with the CETP inhibitor anacetrapibJournal of Lipid Research, 2013
- Effects of Dalcetrapib in Patients with a Recent Acute Coronary SyndromeNew England Journal of Medicine, 2012
- Association of Genetic Variants Influencing Lipid Levels with Coronary Artery Disease in Japanese IndividualsPLOS ONE, 2012
- Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation studyThe Lancet, 2012
- On- and Off-Target Pharmacology of TorcetrapibDrugs, 2012
- China Kadoorie Biobank of 0.5 million people: survey methods, baseline characteristics and long-term follow-upInternational Journal of Epidemiology, 2011
- Biological, clinical and population relevance of 95 loci for blood lipidsNature, 2010
- Genetic variants near TIMP3 and high-density lipoprotein–associated loci influence susceptibility to age-related macular degenerationProceedings of the National Academy of Sciences, 2010
- Major Lipids, Apolipoproteins, and Risk of Vascular DiseaseJAMA, 2009